1. A comparison of central compartment atopic disease and lateral dominant nasal polyps.
- Author
-
Shih, Liang‐Chun, Hsieh, Bing‐Han, Ma, Jia‐Hung, Huang, Shuang‐Shuang, Tsou, Yung‐An, Lin, Chia‐Der, Huang, Kuang‐Hua, and Tai, Chih‐Jaan
- Subjects
- *
NASAL tumors , *NECK dissection , *MUCOCILIARY system , *NASAL polyps , *ALLERGIC rhinitis , *ENDOSCOPIC surgery , *ASIANS , *COMPUTED tomography - Abstract
Background: The characteristics and surgical outcomes of central compartment atopic disease (CCAD) vary by region and race. Therefore, we aimed to identify the risk factors, symptom severity, and prognosis of CCAD in the Asian population. Methods: This case‐control study recruited patients diagnosed with chronic rhinosinusitis with nasal polyps who underwent functional endoscopic sinus surgery (FESS) at a tertiary hospital in Taiwan. Patients were classified into CCAD and lateral‐dominant nasal polyp (LDNP) groups based on endoscopic and computed tomography imaging findings. The demographic data, symptom severity scores, and surgical outcomes of the 2 groups were analyzed. Results: Our study included 442 patients (CCAD group: n = 51; LDNP group: n = 391). We found that CCAD was strongly related to both asthma (9.8% vs 3.5%, p = 0.04) and allergic rhinitis symptoms (43.3% vs 26.6%, p = 0.01). Higher eosinophil counts were detected in blood serum (5.8% vs 2.8%, p < 0.01) and histopathologic profiles (57.0 vs 17.3, p < 0.01) among patients with CCAD. Improvements in 22‐item Sino‐Nasal Outcome Test (SNOT‐22) score and mucociliary clearance time (MCT) after surgical intervention revealed that the CCAD group had a better response to FESS (SNOT‐22 score: −31.82 vs −22.66, p < 0.01; MCT: −233.06 vs −191.93 seconds, p = 0.03). The revision FESS rate was not different between the 2 groups. Conclusion: Polyps originating from the central compartment were found to be related to asthma and allergic rhinitis in Taiwanese patients. A higher eosinophil count was suggested in both serum and local nasal tissue from patients with CCAD. FESS serves as an effective treatment for symptom relief in patients with CCAD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF